Researchers reported that a video assessment developed to measure ease of movement among patients with Duchenne muscular dystrophy (DMD) was clinically meaningful, as published in PLOS One.
Patients with DMD develop progressive muscle weakness. It is vital that clinicians are able to monitor disease progression to optimize treatment. Scientists have developed the Duchenne Video Assessment (DVA), which is a home-based clinical assessment that identifies compensatory movement patterns.
The main advantage of the DVA is that the evaluation is carried out in a home environment. Caregivers are asked to record patients performing certain movements via a secure mobile application.
Read more about DMD etiology
The authors of the study set out to understand how well the DVA performs in achieving its goals and did so through 2 rounds of the study. The first round consisted of panelists evaluating the understandability of compensatory movement criteria through a questionnaire and scorecards developed especially for this assessment.
In the second round, panelists were invited for an in-person meeting to refine areas of disagreement in the first round and to reach a consensus on revisions to the scorecards. By the second round, the panelists reached a 100% agreement on all changes made to the scorecards.
“Physical therapists with extensive experience evaluating patients with DMD confirmed that the compensatory movement criteria included in the DVA scorecards were understandable, comprehensive, and clinically meaningful,” the authors wrote.
By discussing the delineations between different severity levels of compensated movements, the DVA allowed carers to track disease progression in real-time. In addition, should the DVA become used more widely, it can potentially make the evaluation of disease progress more convenient for patients as it eliminates the need to travel to clinical sites.
Contesse MG, Lowes LP, White MK, et al. Development of Duchenne Video Assessment scorecards to evaluate ease of movement among those with Duchenne muscular dystrophy. PLOS One. 2022;17(4):e0266845. doi:10.1371/journal.pone.0266845